12 January 2024
Sidley Represented OnCusp Therapeutics in the Oversubscribed US$100 Million Series A Financing
Advising firms
Deal team
9 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Ruchun Ji Lead | Sidley | Partner | Not stated | Shanghai |
| Geoffrey W. Levin Lead | Sidley | Partner | Not stated | New York |
| Eric Wolf | Sidley | Partner | Not stated | New York |
| James Mendenhall | Sidley | Partner | Not stated | Washington, D.C. |
| Yahel Kaplan | Sidley | Other | Not stated | New York |
| Joel Lifshitz | Sidley | Other | Not stated | New York |
| Carys Golesworthy | Sidley | Senior associate | Not stated | Washington, D.C. |
| Rui Liu | Sidley | Associate | Not stated | Shanghai |
| Milly Kim | Sidley | Trainee | Not stated | New York |
Stated terms
- Stated value
- USD 100m (US$100 million)
- What the figure measures
- Issue size
- Client
- OnCusp Therapeutics, Inc.Issuer
- Counterparties
- Novo Holdings (Investor)
OrbiMed (Investor)
F-Prime Capital (Investor)
Sofinnova Investments (Investor)
Catalio Capital Management (Investor)
Marshall Wace (Investor)
Forge Life Science Partners (Investor)
Blackbird BioVentures (Investor)
CJNV BioVenture (Investor)
BioTrack Capital (Investor)